Bottiger D, Ahgren C, Benthin R, Hogberg M, Oberg B, Sahlberg C, Sahlberg BL, Rydergard C, Uberla K; International Conference on Antiviral Research.
Antiviral Res. 1998 Mar; 37: A55 (abstract no. 52).
Medivir AB, Huddinge, Sweden.
The PETT-4 compounds constitute a series of very potent HIV-1 inhibitors. In vitro inhibition of HIV-1 replication is seen at concentrations down to sub-nanomolar levels. The PETT-4 compounds are HIV-1 specific, like other allosteric HIV-1 reverse transcriptase (RT) inhibitors and thus in vivo evaluation could not be performed in macaques infected with SIV or HIV-2. A chimeric SIV with HIV-1 RT (SHIV) was used for in vivo antiviral evaluation. MSC-206 (3 x 0.5 mg/kg for 5 days), the first PETT-4 compound to be tested in this model, was given to two cynomolgus monkeys in conjunction with SHIV-inoculation (greater than 100 monkey infectious doses i.v.) and the effect on viral antigen appearance was compared to four control animals. The appearance of both viral antigen and viral antibodies were delayed compared to the controls. MSC-206 (3 x 0.5 mg/kg) showed a better antiviral effect against SHIV in cynomolgus macaques than when 3x15 mg/kg of AZT was used. Lower doses of MSC-206 and other PETT-4 compounds are being evaluated in this model.
Publication Types:
Keywords:
- Animals
- Antiviral Agents
- HIV-1
- HIV-2
- In Vitro
- Macaca fascicularis
- Simian immunodeficiency virus
- reverse transcriptase, Human immunodeficiency virus 1
Other ID:
UI: 102236576
From Meeting Abstracts